淀粉样蛋白阴性的轻度认知障碍患者的阿尔茨海默病氟代脱氧葡萄糖正电子发射断层显像模式

Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.

作者信息

Tiepolt Solveig, Patt Marianne, Hoffmann Karl-Titus, Schroeter Matthias L, Sabri Osama, Barthel Henryk

机构信息

Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.

Department of Neuroradiology, University of Leipzig, Leipzig, Germany.

出版信息

J Alzheimers Dis. 2015;47(3):539-43. doi: 10.3233/JAD-150163.

DOI:10.3233/JAD-150163

PMID:26401690

Abstract

The revised NIA-AA diagnostic criteria for Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD make use of amyloid pathology and neurodegeneration biomarkers which increase the diagnostic confidence in the majority of patients. However, in daily praxis, cases with conflicting biomarker constellations occur. A MCI subject underwent neuropsychological testing supplemented by FDG and amyloid PET/MRI as well as CSF sampling. In this subject, the biomarkers of Aβ deposition were negative. [18F]FDG PET, however, showed an AD-typical hypometabolism. Further studies are required to determine frequency and relevance of cases with neurodegeneration-first biomarker constellations to improve our understanding on pathogenesis and diagnosis of AD.

摘要

美国国立衰老研究所（NIA）和美国国立神经疾病与中风研究所（AA）修订的阿尔茨海默病（AD）及AD所致轻度认知障碍（MCI）诊断标准采用了淀粉样蛋白病理学和神经退行性变生物标志物，这提高了大多数患者的诊断可信度。然而，在日常实践中，会出现生物标志物组合相互矛盾的病例。一名MCI受试者接受了神经心理学测试，并辅以氟代脱氧葡萄糖（FDG）和淀粉样蛋白正电子发射断层扫描/磁共振成像（PET/MRI）以及脑脊液采样。在该受试者中，Aβ沉积的生物标志物呈阴性。然而，[18F]FDG PET显示出AD典型的代谢减退。需要进一步研究以确定神经退行性变优先生物标志物组合病例的频率和相关性，以增进我们对AD发病机制和诊断的理解。